Supply Chain Intelligence

Catalyst Pharmaceuticals, Inc. Supply Chain

CPRX supply chain intelligence for Catalyst Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CPRX ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
12Customers
3Debt Items
20Related Chains

Catalyst Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
EISAI EISAI 92% The Company relies on the same third-party manufacturers for FYCOMPA® as utilized by Eisai prior to the Company’s acquisition of the U.S. rights to the product in January 2023.
SANTHERA SANTHERA 90% It also relies on Santhera and its supplier as its sole source of supply for AGAMREE®
SERB-S-A SERB-S-A 90% the Company and its licensor, SERB S.A. ("SERB") have entered into a settlement agreement
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disru…
ORANY ORANY 72% tions by the FDA and other regulatory agencies. If any of our third-party suppliers or contract manufacturers fail to comply with cGMP or other applicable manufacturing regulations, our ability to de…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CPRX graph: tions by the FDA and other regula…

Catalyst Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
JACOBUS-PHARMACEUTICAL-COMPANY-INC JACOBUS-PHARMACEUTICAL-COMPANY-INC 85% is, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net ass…
HETERO-USA-INC HETERO-USA-INC 80% This Settlement Agreement resolves the patent litigation brought by the Company and SERB in response to Hetero's Abbreviated New Drug Application ("ANDA") seeking approval to market a generic version…
APRE Aprea Therapeutics, Inc. 72% Reciprocal relationship from APRE graph: at the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, …
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from ORAN…
ORANY ORANY 72% tions by the FDA and other regulatory agencies. If any of our third-party suppliers or contract manufacturers fail to comply with cGMP or other applicable manufacturing regulations, our ability to de…
PDSB PDS Biotechnology Corporation 72% Reciprocal relationship from PDSB graph: SD International GmbH. Effective May 19, 2017, we entered into a Clinical Trial Collaboration and Supply Agreement (the “CTCSA”) with MSD International GmbH (…
CHIEF-HUMAN-RESOURCES CHIEF-HUMAN-RESOURCES 62% comply with the U.S. Prescription Drug Marketing Act (PDMA), a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Ac…
HEALTH-RESOURCES HEALTH-RESOURCES 62% comply with the U.S. Prescription Drug Marketing Act (PDMA), a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Ac…
HUMAN-RESOURCES HUMAN-RESOURCES 62% comply with the U.S. Prescription Drug Marketing Act (PDMA), a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Ac…
INVENTIA-LIFE-SCIENCE-PTY-LTD INVENTIA-LIFE-SCIENCE-PTY-LTD 62% accounted for pursuant to Topic 606. The agreement included a nonrefundable upfront license fee that was recognized upon the effective date of the agreement as the intellectual property existed at th…
PAR-PHARMACEUTICAL-INC PAR-PHARMACEUTICAL-INC 62% lowing table summarizes the changes in accumulated other comprehensive income, net of tax from unrealized gains (losses) on available-for-sale securities, the Company’s only component of accumulated …

Catalyst Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CPRX-DEBT Debt stack $2.7M 90% Market cache reports total debt of $2.7M.
CPRX-DEBT-8820 Warrants outstanding: 1200000 90% xbrl warrant detail from xbrl 2017-12-31.
CPRX-DEBT-8821 Xbrl Convertible 90% xbrl convertible detail from xbrl 2017-12-31.

Catalyst Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Catalyst Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
CPRX-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 385 tracked holders.

Catalyst Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GNMSF Genmab A/S 100.00 2
SRRK Scholar Rock Holding Corporation 100.00 2
RGNX REGENXBIO Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
HRZN Horizon Technology Finance Corporation 100.00 2
SRPT Sarepta Therapeutics, Inc. 100.00 1 ['spend']
DYN Dyne Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
ORANY ORANGE 100.00 1 ['customer', 'supplier']
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
ARWR Arrowhead Pharmaceuticals, Inc. 100.00 2
HRMY Harmony Biosciences Holdings, Inc. 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
TRDA Entrada Therapeutics, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
CAPR Capricor Therapeutics, Inc. 100.00 2
HTGC Hercules Capital, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
SLDB Solid Biosciences Inc. 100.00 2
View CPRX supply chain intel →

Explore the full interactive supply chain map for Catalyst Pharmaceuticals, Inc..

Open CPRX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map